La “vecchia” polichemioterapia ogni tanto rialza il capo: in due studi recenti e dedicati a neoplasie infrequenti in Occidente, l’aggiunta di un terzo farmaco alle “doppiette” comunemente impiegate sembra delineare nuovi standard di cura.
Bibliografia
- Liu GY, et al. Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ. 2024 Jun 19;385:e077890.
- Kato K, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet 2024; 404:55-66.
